Clinical Trial Update: Phase 1 Open-label Study of 123I-ATT001 in Subjects With Relapsed Glioblastoma [Phase 1]

View source ↗

Summary

A Phase 1 open-label study evaluating the radiopharmaceutical 123I-ATT001 in relapsed glioblastoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• 123I-ATT001 (Iodine-123 ATT001 radiopharmaceutical)

Snippet

Sponsor: Theragnostics Ltd | Conditions: Glioma Glioblastoma Multiforme | Phase 1 | Status: COMPLETED